#USA #Boston #Volta Labs #AGBT #Callisto

Volta Labs at AGBT 2026: Transforming Genomics with Innovative Solutions

On February 26, 2026, Volta Labs made headlines at the AGBT conference by unveiling a series of significant product launches and strategic partnerships. These initiatives are set to position the company at the forefront of the genomics field, marking a pivotal moment in the transformation of genomic sequencing.

New Collaborations and Product Innovations

Volta Labs has expanded its offerings through partnerships with industry giants, including Roche and Watchmaker Genomics. This expansion will enhance the capabilities of their innovative Callisto™ platform, transitioning genomic sequencing from labor-intensive processes to a streamlined, automated workflow.

The integration of Callisto with Roche’s AXELIOS 1 automation solutions is particularly noteworthy. Roche has highlighted the role of Callisto in its AXELIOS 1-compatible automation systems. By ensuring a seamless integration of the SBX-D preparation workflow into Callisto, Volta Labs aims to provide users of next-generation sequencers with a reliable, automated library preparation solution from day one.

Enhancements in Oncology and cfDNA Sequencing

At AGBT, the Hartwig Medical Foundation presented groundbreaking research using Volta Labs’ technology for circulating tumor DNA (ctDNA) in oncology workflows. They showcased how Callisto has enabled automated cfDNA whole genome sequencing, illustrating its capacity for improving patient monitoring, therapy selection, and disease tracking. The presentation included insights into workflow optimization and the operational advantages of utilizing Callisto, emphasizing its ability to accelerate the ligation process significantly.

Launching the Callisto™ Complete Kit

One of the most exciting announcements at the event was the introduction of the Callisto™ Complete Kit, a collaboration with Watchmaker Genomics. This kit facilitates PCR-free whole genome sequencing, optimizing processing time while ensuring high reproducibility and performance, even with challenging samples. This launch signifies a crucial step toward making high-quality whole genome sequencing accessible without increasing workflow complexity or staffing demands.

Together, these developments underscore Callisto’s growing influence as a universal automation platform in modern genomics, supporting various sequencers, reagents, and assays under one cohesive system.

Real-World Validation of Callisto

During the conference, esteemed institutions like UMC Utrecht and the Hartwig Medical Foundation provided real world data demonstrating the effectiveness of Callisto in high-throughput environments. Both organizations reported significant improvements in operational efficiency, consistency, and reproducibility, validating Volta Labs’ innovative approach.

Bert Van der Zwaag, a laboratory specialist in clinical genetics at UMC Utrecht, commented on their success with Callisto. Since adopting the platform, they have processed thousands of patient samples, significantly surpassing their initial capacity. The implementation of Callisto has allowed them to standardize laboratory workflows, enhancing protocols for ctDNA and other critical applications.

Pioneering Change in Genomic Applications

Volta Labs continues to drive a shift towards application-based genomics by introducing a growing lineup of pre-developed applications expected to launch by 2026. This strategic move aims to replace costly and repetitive method development with validated workflows, fostering a more efficient and accessible genomic landscape.

Udayan Umapathi, CEO of Volta Labs, expressed the vision for the future: “Innovations in sequencing should not require every lab to reinvent their workflow. We are accelerating the industry's shift toward truly automated genomics, where sequencing at the push of a button becomes the norm, not the exception.”

About Volta Labs

Founded in Boston, Massachusetts, Volta Labs is at the forefront of revolutionizing sequencing sample preparation. By integrating digital fluidics, modular workflows, and complete walk-away automation into a single platform, Callisto™ enables high-quality, reproducible NGS library preparation for whole-genome, targeted, and custom applications. The company's innovative solutions are set to redefine the standards of genomic research and clinical applications around the globe.